Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.

[1]  I. Komuro,et al.  Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction , 2001, Cardiovascular Drugs and Therapy.

[2]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Jiang,et al.  Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[5]  G. Beatch,et al.  Kinetics of rate‐dependent shortening of action potential duration in guinea‐pig ventricle; effects of IK1 and IKr blockade , 1999, British journal of pharmacology.

[6]  H. Nakaya,et al.  Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug , 1998 .

[7]  M. Omata,et al.  Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? , 1997, Journal of the American College of Cardiology.

[8]  K. Kamiya,et al.  Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. , 1996, Cardiovascular research.

[9]  Christopher Miller.  The inconstancy of the human heart , 1996, Nature.

[10]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[11]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[12]  I. Hisatome,et al.  A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. , 1995, The Journal of pharmacology and experimental therapeutics.

[13]  Y. Nakaya,et al.  Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. , 1995, Pharmacology & toxicology.

[14]  Y. Hara,et al.  Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. , 1995, Circulation.

[15]  A. Camm,et al.  Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). , 1995, The American journal of cardiology.

[16]  A. Hirasawa,et al.  Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. , 1995, Japanese journal of pharmacology.

[17]  L. Chi,et al.  MS‐551 Protects Against Ventricular Fibrillation in a Chronic Canine Model of Sudden Cardiac Death , 1995, Journal of cardiovascular pharmacology.

[18]  K. Umemura,et al.  Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction Model , 1994, Journal of cardiovascular pharmacology.

[19]  L. Chi,et al.  Antiarrhythmic Agent, MS‐551, Protects Against Pinacidil + Hypoxia‐Induced Ventricular Fibrillation in Langendorff‐Perfused Rabbit Isolated Heart , 1994, Journal of cardiovascular pharmacology.

[20]  E. Carmeliet.  Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. , 1993, Circulation research.

[21]  J. Mason.  A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.

[22]  H. Nakaya,et al.  Effects of MS‐551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes , 1993, British journal of pharmacology.

[23]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[24]  B F Hoffman,et al.  Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.

[25]  S. Yasuda,et al.  Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. , 2001, Japanese circulation journal.

[26]  Baofeng Yang,et al.  Transmembrane I Ca contributes to rate-dependent changes of action potentials in human ventricular myocytes. , 1999, American journal of physiology. Heart and circulatory physiology.

[27]  M. Ishii,et al.  Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. , 1992, Japanese journal of pharmacology.